1801:HKEXInnovent Biologics, Inc. Analysis
Data as of 2026-03-13 - not real-time
CN¥1.90
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Bosera China Merchants Shekou Industrial Zone (1801) trades at a strikingly low PE of 1.3x and PB of 0.86x, well below its 20‑day SMA of 1.97 and 50‑day SMA of 1.96, suggesting a deep value opportunity. However, revenue has contracted by 10.3% YoY, margins are modest (gross 39%, operating 21%) and the balance sheet is strained with a debt‑to‑equity ratio of over 9, leaving net debt concerns. The stock sits near its technical support at 1.891 CNY, with a low RSI of 31 indicating oversold conditions, while MACD remains bearish and volume is trending downwards.
Recent contract sales reported for June/H1 provide a modest operational catalyst, but the broader Chinese infrastructure and real‑estate regulatory environment adds headwinds. Market sentiment appears optimistic (Fear & Greed Index 73 – “Greed”), yet the combination of high leverage, negative growth, and decreasing liquidity suggests caution.
Recent contract sales reported for June/H1 provide a modest operational catalyst, but the broader Chinese infrastructure and real‑estate regulatory environment adds headwinds. Market sentiment appears optimistic (Fear & Greed Index 73 – “Greed”), yet the combination of high leverage, negative growth, and decreasing liquidity suggests caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price hovering at technical support (1.891 CNY)
- Bearish MACD and decreasing volume
- Oversold RSI indicating limited upside potential
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Deep valuation gaps (PE 1.3x, PB 0.86x)
- High debt‑to‑equity ratio (~9.4) limiting financial flexibility
- Neutral trend with mixed technical signals
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant undervaluation relative to earnings and book value
- Potential upside from infrastructure demand and contract sales
- Market optimism reflected in a high Fear & Greed index
Key Metrics & Analysis
Financial Health
Revenue Growth-10.30%
Profit Margin21.67%
P/E Ratio1.3
ROE1.35%
ROA0.85%
Debt/Equity9.36
P/B Ratio0.9
Op. Cash FlowCN¥120.5M
Free Cash FlowCN¥163.1M
Technical Analysis
TrendNeutral
RSI31.5
SupportCN¥1.89
ResistanceCN¥2.02
MA 20CN¥1.97
MA 50CN¥1.96
MA 200CN¥2.02
MACDBearish
VolumeDecreasing
Fear & Greed Index73.38
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta-0.00
Volatility14.84%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.